Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Am J Cardiol ; 117(12): 1917-20, 2016 06 15.
Artículo en Inglés | MEDLINE | ID: mdl-27134059

RESUMEN

Increased plasma levels of neuron-specific enolase (NSE) are related to damage of neurons and neuroendocrine cells. We aimed to investigate elevation of NSE after elective percutaneous coronary intervention (PCI) on the prediction of silent cerebral infarct (SCI). Study population consisted of 2 groups of patients. Group 1 included 92 consecutive patients with normal coronary angiograms, whereas group 2 consisted of 89 patients who underwent elective coronary stenting. NSE levels were studied before and 12 hours after the procedure. Elevation of >0.12 µg/L was considered as SCI. Forty-seven of 181 study patients (26%) had SCI after the procedure. NSE elevation was significantly more prevalent in patients with PCI than that of controls. Elevation of NSE was observed in 42% of patients who underwent elective PCI (n = 37) and 11% of the normal coronary artery group (n = 10) (p <0.001). The incidence of SCI was higher in active smokers and patients who had history of myocardial infarction (MI) (55% vs 10%, p <0.001 for active smokers and 40% vs 8%, p <0.001 for history of MI, respectively). Multivariate analysis demonstrated history of smoking (odds ratio [OR] 9.9; 95% confidence interval [CI] 3.7 to 26.9; p <0.001) and previous MI (OR 4.4; 95% CI 1.7 to 11.4; p = 0.01) as independent predictors of SCI. For patients who underwent elective PCI, NSE levels after procedure increases. Invasive coronary procedures have risk of SCIs, even in patients with normal coronary arteries. In conclusion, increased diagnosis of SCIs might improve understanding of their relation with invasive cardiac procedures, facilitate to prevent occurrence of silent microemboli and decrease the risk of adverse neurologic events.


Asunto(s)
Infarto Cerebral/enzimología , Estenosis Coronaria/cirugía , Intervención Coronaria Percutánea/efectos adversos , Fosfopiruvato Hidratasa/sangre , Medición de Riesgo/métodos , Stents , Biomarcadores/sangre , Infarto Cerebral/epidemiología , Infarto Cerebral/etiología , Estenosis Coronaria/enzimología , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Factores de Riesgo , Factores de Tiempo , Turquía/epidemiología
3.
Turk Kardiyol Dern Ars ; 43(1): 89-92, 2015 Jan.
Artículo en Turco | MEDLINE | ID: mdl-25655858

RESUMEN

In order to reduce sudden cardiac death and heart failure symptoms, biventricular implantable cardioverter defibrillator (ICD) implantation is a treatment method commonly used in selected patients with cardiomyopathy. The frequency of dextrocardia in congenital heart defects is approximately 0.4/10000. In this group, the frequency of cardiomyopathy development is rare. In this case report we present a patient with dextrocardia undergoing implantation of biventricular ICD.


Asunto(s)
Desfibriladores Implantables , Dextrocardia/cirugía , Situs Inversus/cirugía , Anciano , Humanos , Masculino
4.
J Interv Card Electrophysiol ; 38(2): 143-5, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23080329

RESUMEN

Vancomycin is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive resistant bacteria. In recent years, several cases of vancomycin-associated immune thrombocytopenia have been presented as case reports, but the real incidence of this side effect is still unknown. In this report, we would like to present a case during which we confronted with a great dilemma: urgent removal of whole defibrillator system due to highly suspected infective endocarditis or leaving the defibrillator in place and simply switching vancomycin to another antibiotic agent and wait.


Asunto(s)
Enfermedades Autoinmunes/inducido químicamente , Enfermedades Autoinmunes/diagnóstico , Endocarditis/diagnóstico , Endocarditis/etiología , Trombocitopenia/inducido químicamente , Trombocitopenia/diagnóstico , Vancomicina/efectos adversos , Antibacterianos/efectos adversos , Enfermedades Autoinmunes/prevención & control , Remoción de Dispositivos , Diagnóstico Diferencial , Endocarditis/prevención & control , Femenino , Humanos , Persona de Mediana Edad , Marcapaso Artificial/efectos adversos , Infecciones Relacionadas con Prótesis/diagnóstico , Infecciones Relacionadas con Prótesis/etiología , Infecciones Relacionadas con Prótesis/prevención & control , Trombocitopenia/prevención & control , Resultado del Tratamiento
5.
J Thromb Thrombolysis ; 34(1): 65-72, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22252901

RESUMEN

We aimed to examine whether intracoronary high-dose bolus of tirofiban plus maintenance would result in improved clinical outcome in STEMI patients undergoing primary PCI in this pilot trial. A total of 56 patients were enrolled to receive either intracoronary high-dose bolus plus maintenance (n = 34) or intravenous high-dose bolus plus maintenance (n = 22) of tirofiban. Pre and post intervention TIMI flow grades, myocardial blush grades, peak CKMB and troponin levels, time to peak CKMB and troponin, time to 50% ST resolution and major composite adverse cardiac event rates at 30 days were recorded. Although incidence of major adverse cardiac events was not different, post intervention TIMI flow and TIMI blush grades, peak CKMB and troponin levels, and time to peak CKMB and time to peak troponin were significantly different, favoring intracoronary strategy. In conclusion, this regimen improved myocardial reperfusion and coronary flow, and reduced myocardial necrosis, but failed to improve clinical outcomes at 30 days.


Asunto(s)
Angioplastia Coronaria con Balón , Infarto del Miocardio/terapia , Inhibidores de Agregación Plaquetaria/administración & dosificación , Tirosina/análogos & derivados , Anciano , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Infarto del Miocardio/patología , Necrosis , Proyectos Piloto , Inhibidores de Agregación Plaquetaria/efectos adversos , Factores de Tiempo , Tirofibán , Tirosina/administración & dosificación , Tirosina/efectos adversos
6.
Coron Artery Dis ; 18(3): 159-62, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17429287

RESUMEN

OBJECTIVE: The relationship between androgens and the risk of development of coronary artery disease has not been clarified well. This study was planned to determine the relationship between serum androgen levels and premature development of coronary artery disease in men. METHODS: Sixty-nine men below 45 years of age with documented coronary artery disease (mean age 41.0+/-4.7) constituted the study group. Control group consisted of 56 men with similar age and normal coronary angiograms (mean age 41.3+/-3.8). Total and free testosterone, estradiol, and fasting plasma total, low-density lipoprotein, and high-density lipoprotein cholesterol, and triglyceride levels were measured, and compared between the two groups. RESULTS: Mean age, body mass index, and the frequency of hypertension were similar between the two groups; however, diabetes mellitus, smoking, hyperlipidemia, and family history of coronary artery disease were more frequent in the coronary artery disease group. Total and free testosterone levels of the patients with coronary artery disease were significantly lower than those of controls, whereas estradiol levels did not differ. Multivariate logistic regression analysis revealed that free testosterone levels (P=0.014; odds ratio=0.90; 95% confidence interval=0.87-0.99), hyperlipidemia (P<0.001; odds ratio=8.2; 95% confidence interval=3.17-21.0), and smoking (P=0.026; odds ratio=3.12; 95% confidence interval=1.15-8.48) were independent predictors of premature coronary artery disease. Moreover, using receiver operating characteristic analysis, patients with free testosterone levels below the cut-off value of 17.3 pg/ml had an adjusted 3.3-fold risk of developing premature coronary artery disease compared to those with free testosterone levels above the cut-off level (odds ratio=3.3; 95% confidence interval=1.57-6.87). CONCLUSION: A low level of free testosterone may be related to the development of premature coronary artery disease.


Asunto(s)
Andrógenos/sangre , Enfermedad de la Arteria Coronaria/sangre , Adulto , Estudios de Casos y Controles , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Estradiol/sangre , Humanos , Masculino , Persona de Mediana Edad , Testosterona/sangre , Triglicéridos/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA